<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00509808</url>
  </required_header>
  <id_info>
    <org_study_id>1-Wolff</org_study_id>
    <nct_id>NCT00509808</nct_id>
  </id_info>
  <brief_title>Evaluation of an Electro-stimulator for the Treatment of Xerostomia</brief_title>
  <acronym>GenNarino</acronym>
  <official_title>Safety and Performance Evaluation of an Electro-stimulator Mounted on an Intra-oral Removable Appliance (Saliwell GenNarino) for the Treatment of Xerostomia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saliwell Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad El Bosque, Bogotá</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zagreb</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>McGill University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hebrew University of Jerusalem</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universita degli Studi di Palermo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Nacional Autonoma de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Brasilia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Carlos, Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Kentucky</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Helsinki</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Saliwell Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multinational trial, aimed at testing the safety and performance of a&#xD;
      electrostimulating device (&quot;GenNarino&quot;) to treat dry mouth, over one year. The design is as&#xD;
      follows:&#xD;
&#xD;
        -  Multi-center, double blind, sham (placebo) controlled, about 10 xerostomia patients per&#xD;
           center&#xD;
&#xD;
        -  Patients receive a GenNarino (and its remote control) that is programmed for one month&#xD;
           sham and one month active mode (the order of which is randomly assigned), and thereafter&#xD;
           9 months at the active mode (divided in period of 3 months, the order of each is&#xD;
           randomly assigned at wearing GenNarino for 1, 5 or 10 minutes at a time).&#xD;
&#xD;
      Study hypothesis: Gennarino will lead to significant symptomatic improvement&#xD;
&#xD;
      - At the clinic: monthly examinations at the first 2 months, and then every 3 months,&#xD;
      including whole saliva collection and questionnaire; at the first visit impression taking for&#xD;
      GenNarino preparation&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The clinical trial, titled &quot;Safety and performance evaluation of an electro-stimulator&#xD;
      mounted on an intra-oral removable appliance (GenNarino) for the treatment of xerostomia&quot; is&#xD;
      a prospective, randomized, double-blind, sham-controlled multi-center trial, followed by an&#xD;
      open-label study. Study subjects are patients with xerostomia. The purpose of the trial is to&#xD;
      test the safety and efficacy of electrostimulation using the GenNarino device.&#xD;
&#xD;
      The primary endpoint is significant symptomatic improvement, and the secondary ones,&#xD;
      increased salivary output and event free use (no adverse side-effects). The clinical&#xD;
      follow-up consists of periodic clinical examinations.&#xD;
&#xD;
      In this clinical trial the use of the device is compared between active vs. sham mode for one&#xD;
      month each in a double-blind design (Stage I). Thereafter, at Stage II the xerostomia&#xD;
      relieving effect of the active device is assessed in an open label design for additional 6&#xD;
      months. Clinic- and home-based questionnaires and whole saliva collections are performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant symptomatic improvement</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1- Increased salivary output 2- Event free use (no adverse side-effects)</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Xerostomia</condition>
  <arm_group>
    <arm_group_label>electrostimulation</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Use of device for predetermined length</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electrostimulation</intervention_name>
    <description>1st month GN wearing (activated or sham mode)&#xD;
2nd month wearing (opposite mode)&#xD;
3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes&#xD;
6th - 8th month: activated GN wearing for 1, 5 or 10 minutes&#xD;
9th - 11th month: activated GN wearing for 1, 5 or 10 minutes</description>
    <arm_group_label>electrostimulation</arm_group_label>
    <other_name>GenNarino</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The patient must be at least 18 years of age.&#xD;
&#xD;
          2. The patient must have clinical symptoms of xerostomia (dry mouth) due to&#xD;
&#xD;
               -  Primary or secondary Sjögren's syndrome&#xD;
&#xD;
               -  Medication intake&#xD;
&#xD;
               -  Head and neck radiation with survival expectancy of more than one year&#xD;
&#xD;
               -  Chronic graft vs. host disease with survival expectancy of more than one year&#xD;
&#xD;
          3. Patients are requested not to take systemic sialogogues during the first 2 months of&#xD;
             the study (when active is tested vs. sham)&#xD;
&#xD;
          4. Female patients of child bearing potential must have a negative pregnancy test within&#xD;
             twenty-four hours of enrollment.&#xD;
&#xD;
          5. The patient must understand and consent in writing to the procedure.&#xD;
&#xD;
          6. The patient agrees to undergo all examinations and clinical evaluations planned for&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active HIV or HCV infection&#xD;
&#xD;
          2. Severe systemic disease&#xD;
&#xD;
          3. Known allergy to materials similar to be used in the investigational product&#xD;
&#xD;
          4. Known mental disease&#xD;
&#xD;
          5. Presence of depression, by positive answers to both the following questions:&#xD;
&#xD;
               -  &quot;During the past month have you often been bothered by feeling down, depressed or&#xD;
                  hopeless?&quot;&#xD;
&#xD;
               -  &quot;During the past month have you often been bothered by little interest or&#xD;
                  pleasure in doing things?&quot;&#xD;
&#xD;
          6. Patients wearing other active implants like pacemaker or defibrillator&#xD;
&#xD;
          7. Patients with poor oral hygiene&#xD;
&#xD;
          8. Patients whose oral anatomical characteristics precludes the insertion of the device&#xD;
&#xD;
          9. Patients who are unable or unwilling to cooperate with study procedures.&#xD;
&#xD;
         10. Pregnancy&#xD;
&#xD;
         11. Presence of erosive or ulcerative oral lesions, which are chronic or recurrent, such&#xD;
             as erosive lichen planus, RAS, eryth. Candidosis, and of suspected pre-malignant or&#xD;
             malignant lesions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andy Wolff, DMD</last_name>
    <role>Study Director</role>
    <affiliation>Saliwell Ltd.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital and University of Helsinki</name>
      <address>
        <city>Helsinki</city>
        <zip>00014</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>July 31, 2007</study_first_submitted>
  <study_first_submitted_qc>July 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 1, 2007</study_first_posted>
  <last_update_submitted>April 5, 2010</last_update_submitted>
  <last_update_submitted_qc>April 5, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Andy Wolff</name_title>
    <organization>Saliwell Ltd.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

